DB:ELNJ

Stock Analysis Report

Executive Summary

Elanix Biotechnologies AG develops and commercializes products for acute wound care, and dermatological and gynecological applications.


Snowflake Analysis

Mediocre balance sheet with weak fundamentals.

Share Price & News

How has Elanix Biotechnologies's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ELNJ's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

ELNJ

-2.3%

DE Biotechs

-0.2%

DE Market


1 Year Return

-32.6%

ELNJ

8.4%

DE Biotechs

13.7%

DE Market

Return vs Industry: ELNJ underperformed the German Biotechs industry which returned 8.4% over the past year.

Return vs Market: ELNJ underperformed the German Market which returned 13.7% over the past year.


Shareholder returns

ELNJIndustryMarket
7 Day0%-2.3%-0.2%
30 Day-0.5%-3.2%0.3%
90 Day-24.2%6.3%3.7%
1 Year-32.6%-32.6%8.6%8.4%17.2%13.7%
3 Yearn/a44.5%42.9%15.4%5.3%
5 Yearn/a13.0%10.6%21.3%4.7%

Price Volatility Vs. Market

How volatile is Elanix Biotechnologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Elanix Biotechnologies undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Elanix Biotechnologies is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Elanix Biotechnologies has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of ELNJ’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Elanix Biotechnologies regulatory filings.
  • Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.

Future Growth

How is Elanix Biotechnologies forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

35.5%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Elanix Biotechnologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Elanix Biotechnologies performed over the past 5 years?

22.3%

Historical Pharmaceuticals & Biotech annual earnings growth


Earnings and Revenue History

Quality Earnings: Insufficient data to determine if ELNJ has high quality earnings.

Growing Profit Margin: Insufficient data to determine if ELNJ's profit margins have improved over the past year.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if ELNJ's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Insufficient data to compare ELNJ's past year earnings growth to its 5-year average.

Earnings vs Industry: Insufficient data to determine if ELNJ's earnings growth over the past year exceeded the Biotechs industry average.


Return on Equity

High ROE: ELNJ has a negative Return on Equity (0%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Elanix Biotechnologies's financial position?


Financial Position Analysis

Short Term Liabilities: Insufficient data to determine if ELNJ's short term assets cover its short term liabilities.

Long Term Liabilities: ELNJ has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: ELNJ is debt free.

Reducing Debt: ELNJ has no debt compared to 5 years ago when its debt to equity ratio was 0.01%.


Balance Sheet

Inventory Level: Insufficient data to determine if ELNJ has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if ELNJ's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if ELNJ has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ELNJ has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Elanix Biotechnologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.7%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate ELNJ's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ELNJ's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ELNJ's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ELNJ's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ELNJ's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.8yrs

Average board tenure


CEO

Lee-Ann Laurent-Applegate 0

0

Prof. Lee-Ann Laurent-Applegate serves as Chief Executive Officer of Elanix Biotechnologies AG. 


Board Members

NamePositionTenureCompensationOwnership
Zhanfeng Cui
Member of the Supervisory Board0.8yrsno datano data
Fang Bao
Vice Chairman of Supervisory Board0.8yrsno datano data
Anja Silling
Chairman of Supervisory Board0.8yrsno data12.85% 466.3k

0.8yrs

Average Tenure

Experienced Board: ELNJ's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.


Top Shareholders

Company Information

Elanix Biotechnologies AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Elanix Biotechnologies AG
  • Ticker: ELNJ
  • Exchange: DB
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €3.628m
  • Shares outstanding: 8.08m
  • Website: https://elanixbiotechnologies.com

Number of Employees


Location

  • Elanix Biotechnologies AG
  • Tomas Svoboda (Vorstand)
  • Domstrasse, 22
  • Potsdam
  • Brandenburg
  • 14482
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ELNDB (Deutsche Boerse AG)YesCommon StockDEEURNov 1998
ELNXTRA (XETRA Trading Platform)YesCommon StockDEEURNov 1998
0NQALSE (London Stock Exchange)YesCommon StockGBEURNov 1998
ELNJDB (Deutsche Boerse AG)NPV NEW SHARESDEEURAug 2018

Biography

Elanix Biotechnologies AG develops and commercializes products for acute wound care, and dermatological and gynecological applications. The company develops and markets progenitor cell-based products that are used to regenerate tissue and promote healing in the treatment of burns, and gynecological and dermatological conditions. Its products include GYNrepair, a cream for genital external mucosa; and SKINrepair, a cream for skin that protects against external aggressions. The company is also developing FirstCover, an acute wound care tissue engineering product that is used to provide protection and healing for burns, and trauma and plastic surgery. In addition, it offers cell technology services. Elanix Biotechnologies AG has a co-development agreement with Dermacon GmbH to develop medical devices for its wound care franchise. The company was formerly known as Porta Systems AG and changed its name to Elanix Biotechnologies AG in December 2015. Elanix Biotechnologies AG is based in Potsdam, Germany. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/20 23:51
End of Day Share Price2020/02/10 00:00
Earnings2018/06/30
Annual Earnings2017/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.